Guggenheim Capital’s Sinovac Biotech, Ltd SVA Stock Holding History

Guggenheim Capital’s Portfolio SVA Stock Details SVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-20,840	Closed	-$179K	–	2820
2018 Q1	$179K	Sell	20,840 -1,059	-5%	-$8.73K	﹤0.01%	2631
2017 Q4	$173K	Buy	21,899 +3,517	+19%	+$26.3K	﹤0.01%	2582
2017 Q3	$129K	Buy	18,382 +91	+0.5%	+$621	﹤0.01%	2643
2017 Q2	$123K	Sell	18,291 -459	-2%	-$2.52K	﹤0.01%	2683
2017 Q1	$107K	Sell	18,750 -2,676	-12%	-$15.5K	﹤0.01%	2689
2016 Q4	$126K	Sell	21,426 -3,329	-13%	-$20K	﹤0.01%	2751
2016 Q3	$146K	Buy	24,755 +37	+0.1%	+$218	﹤0.01%	2697
2016 Q2	$147K	Sell	24,718 -1,672	-6%	-$10.2K	﹤0.01%	2704
2016 Q1	$169K	Sell	26,390 -2,798	-10%	-$16.8K	﹤0.01%	2707
2015 Q4	$167K	Buy	+29,188	New	+$157K	﹤0.01%	2791

Other funds holding SVA

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NAH

Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SSP

Sapphire Star Partners Redmond, Washington $74.7M AUM 5.87% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

YMRC

Yorktown Management & Research Company Forest, Virginia $120M AUM 52.72% 1-Year Est. Return

FIM

Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return

SIM

Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

Guggenheim Capital's SVA Position: Q2 2018 in Review

Guggenheim Capital sold out of Sinovac Biotech, Ltd (SVA) in Q2 2018, closing a stake of 20,840 shares — an estimated $179K sold.

Guggenheim Capital first reported a position in SVA in Q4 2015 and held it in 10 quarters. The position peaked at $179K in Q1 2018. 29 funds tracked by Wall St. Rank hold SVA as of Q2 2018.

Guggenheim Capital reported no remaining Sinovac Biotech, Ltd position as of Q2 2018 after selling out during the quarter.
Guggenheim Capital sold 20,840 Sinovac Biotech, Ltd shares in Q2 2018, an estimated $179K.
Guggenheim Capital first reported a position in Sinovac Biotech, Ltd in Q4 2015 and held it in 10 quarters.
Guggenheim Capital's Sinovac Biotech, Ltd position peaked at $179K in Q1 2018.
29 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2018.

Based on Guggenheim Capital's 13F filing for Q2 2018, filed 14 Aug 2018.